About Biobank/Biomarkers

Since 1994, NCARD has created a biobank of patient samples to facilitate research aimed at delivering improved clinical outcomes to the people of Western Australia and around the world.

Based at Sir Charles Gairdner Hospital (SCGH), the NCARD Biobank consists of a group of clinicians and scientists dedicated to medical research focused on improving diagnosis and treatment of asbestos-related diseases such as mesothelioma, as well as other health conditions. The Biobank has been partially funded by a National Health and Medical Research Council Centre of Research Excellence grant.

The biobank has supported over thirty different projects with approximately 10,000 bio specimens prepared from de-identified samples donated for medical research. In addition, around 80 cancer cell lines have been established.

If you have any questions about the NCARD Biobank, you can contact the Biobank Manager, Professor Jenette Creaney on (08) 6151 0896 or

Research Projects

Characterising and exploiting common genetic alterations in mesothelioma for improved patient outcomes
Identification and validation of biomarkers for mesothelioma
Laboratory tests to understand why some patients with mesothelioma respond better to a combination of chemotherapy and immunotherapy
Molecular mechanisms of response and resistance to immunotherapy in mesothelioma
Understanding the genetics of malignant mesothelioma susceptibility and prognosis


Professor Jenette Creaney explains the Biobank and biomarkers.